Michael Derrer Fuchs/iStock Editorial via Getty Images
Novartis (NYSE:NVS) (OTCPK:NVSEF) (TSX:NVS:CA) said Sunday it will acquire California-based Avidity Biosciences (NASDAQ:RNA) in a $12 billion all-cash transaction, strengthening the Swiss pharmaceutical company’s portfolio of treatments for rare muscle disorders.
According to the agreement, Avidity (NASDAQ:RNA) shareholders will
#Novartis #buy #Avidity #Biosciences #12B #deal #boost #rare #disease #pipeline #NVSNYSE